Intravitreal vascular endothelial growth factor (VEGF) inhibitor injection in unrecognised early pregnancy

被引：10

作者：

Kianersi, Farzan ^{[1
]}

Ghanbari, Heshmatollah ^{[1
]}

Beni, Zahra Naderi ^{[2
]}

Beni, Afsaneh Naderi ^{[3
]}

机构：

[1] Isfahan Univ Med Sci, Dept Ophthalmol, Esfahan, Iran

[2] Isfahan Univ Med Sci, Dept Radiotherapy & Oncol, Esfahan, Iran

[3] Shahrekord Univ Med Sci, Dept Ophthalmol, Shahrekord, Iran

来源：

INVESTIGATIONAL NEW DRUGS | 2016年 / 34卷 / 05期

关键词：

Intravitreal vascular endothelial growth factor; Pregnancy; Complication; CHOROIDAL NEOVASCULARIZATION; BEVACIZUMAB INJECTION; AVASTIN;

D O I：

10.1007/s10637-016-0361-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The use of intravitreal vascular endothelial growth factor (VEGF) inhibitor medications has widened considerably to include indications affecting females of reproductive age. Our patient was inadvertently exposed to bevacizumab within the first trimester when placental growth and fetal organogenesis take place and patient suffered pregnancy loss. There is insufficient information to suggest that such use is safe, nor is there definitive evidence to suggest that it causes harm. We advise that ophthalmologists discuss pregnancy with women of childbearing age undergoing intraocular anti-VEGF injections and in pregnant woman counselling is needed to explain the potential risks and benefits.

引用

页码：650 / 653

页数：4

共 16 条

[1] Pharmacokinetics of intravitreal bevackumab (avastin)
Bakri, Sophie J.
Snyder, Melissa R.
Reid, Joel M.
Pulido, Jose S.
Singh, Ravinder J.
[J]. OPHTHALMOLOGY, 2007, 114 (05) : 855 - 859
[2] Briggs G.G., 2011, Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk
[3] Safety Implications of Vascular Endothelial Growth Factor Blockade for Subjects Receiving Intravitreal Anti-Vascular Endothelial Growth Factor Therapies
Csaky, Karl
Do, Diana V.
[J]. AMERICAN JOURNAL OF OPHTHALMOLOGY, 2009, 148 (05) : 647 - 656
[4] Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature
Falavarjani, K. Ghasemi
Nguyen, Q. D.
[J]. EYE, 2013, 27 (07) : 787 - 794
[5] The International Intravitreal Bevacizumab Safety Survey: using the Internet to assess drug safety worldwide
Fung, A. E.
Rosenfeld, P. J.
Reichel, E.
[J]. BRITISH JOURNAL OF OPHTHALMOLOGY, 2006, 90 (11) : 1344 - 1349
[6] Intravitreal Bevacizumab for a Subfoveal Myopic Choroidal Neovascularization in the First Trimester of Pregnancy
Introini, Ugo
Casalino, Giuseppe
Cardani, Anna
Scotti, Fabrizio
Finardi, Alberto
Candiani, Massimo
Bandello, Francesco
[J]. JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2012, 28 (05) : 553 - 555
[7] Early loss of pregnancy after intravitreal bevacizumab injection
Petrou, Petros
Georgalas, Ilias
Giavaras, Georgios
Anastasiou, Eleni
Ntana, Zoi
Petrou, Constantinos
[J]. ACTA OPHTHALMOLOGICA, 2010, 88 (04) : e136 - e136
[8] Exposure to verteporfin and bevacizumab therapy for choroidal neovascularization secondary to punctate inner choroidopathy during pregnancy
Rosen, E.
Rubowitz, A.
Ferencz, J. R.
[J]. EYE, 2009, 23 (06) : 1479 - 1479
[9] Intravitreal Administration of Ranibizumab for Idiopathic Choroidal Neovascularization in a Pregnant Woman
Sarhianaki, A.
Katsimpris, A.
Petropoulos, I. K.
Livieratou, A.
Theoulakis, P. E.
Katsimpris, J. M.
[J]. KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE, 2012, 229 (04) : 451 - 453
[10] Vascular endothelial growth factor in fellow eyes of eyes injected with intravitreal bevacizumab
Sawada, Osamu
Kawamura, Hajime
Kakinoki, Masashi
Ohji, Masahito
[J]. GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2008, 246 (10) : 1379 - 1381

← 1 2 →